Pharmaceutical Exporter from India to Africa.
Africa is the largest block of our export footprint. M Care Exports supplies WHO-GMP finished dosage forms from Indian manufacturers into eight regulated markets across the continent: Nigeria, Kenya, Ghana, South Africa, Ethiopia, Tanzania, Uganda and Egypt. The Mumbai desk authors CTD and eCTD dossiers for NAFDAC, PPB, FDA Ghana, SAHPRA, EFDA, TMDA, NDA and EDA in parallel and runs warm-climate cold-chain lanes into Lagos, Mombasa, Durban, Addis Ababa and Accra. We bid into central-stores framework tenders and supply NGO and donor-funded programme buyers across the continent.
Five-plus authorities, one dossier strategy.
Africa does not register pharmaceuticals from a single desk. A multi-country programme touches at least five national regulators, each with its own CTD variant and timing. NAFDAC (National Agency for Food and Drug Administration and Control, Nigeria) runs review through the NMR e-portal on a six-to-twelve-month window, with physical port-of-entry inspection standard. PPB (Pharmacy and Poisons Board, Kenya) takes six to nine months on WHO-PQ reference products. FDA Ghana lands inside eight to twelve months. SAHPRA (South African Health Products Regulatory Authority) is the strictest at twelve to eighteen months, with an accelerated pathway for priority public-health products.
EFDA (Ethiopian Food and Drug Authority), TMDA (Tanzania Medicines and Medical Devices Authority), NDA (National Drug Authority, Uganda) and EDA (Egyptian Drug Authority) round out the eight authorities most M Care Exports consignments clear. EFDA requires local-agent representation. EDA governs North Africa's largest pharma market and mandates Arabic artwork. The AMA (African Medicines Agency) treaty entered into force on 5 November 2019, the secretariat is being stood up in Kigali, and operational rollout is phased through the late 2020s. The EAC Medicines Regulatory Harmonization programme already runs joint assessments for Kenya, Uganda, Tanzania, Rwanda and Burundi, with a single dossier and mutually recognised registration for ARV, ACT and TB categories.
Procurement in much of Africa flows through state central medical stores rather than open-market purchase orders. KEMSA (Kenya Medical Supplies Authority) and the faith-based MEDS cover most public-sector Kenya demand. NMS (National Medical Stores, Uganda) and JMS (Joint Medical Store, Uganda) split the public and FBO channels. MSD (Medical Stores Department, Tanzania), CMS Ghana and EPSS (Ethiopian Pharmaceuticals Supply Service) anchor their respective markets. Tender cycles run two to three years, with WHO-PQ preferred or mandatory for programmatic buys on ARVs, ACTs and TB fixed-dose combinations. We bid into refresh rounds across the continent on a quarterly cadence.
The Francophone and Anglophone divide matters. UEMOA and ECOWAS WAHO (West African Health Organisation) drive harmonisation across Francophone West Africa, with OCEAC covering the Francophone Central African block. ARV and ACT fast-tracks run under WAHO. Anglophone West Africa routes through ECOWAS WAHO but sits closer to the Anglophone dossier conventions serving NAFDAC and FDA Ghana. AMA is the convergence point for all of these tracks, and dossiers we author today are structured to re-use across AMA, EAC, WAHO and WHO-PQ without a ground-up rebuild.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · [email protected] · Mon–Sat 09:30–18:30 IST
Six capabilities, pre-assembled.
NAFDAC, PPB, FDA Ghana, SAHPRA dossiers
The Mumbai regulatory team authors CTD and eCTD dossiers for NAFDAC, PPB, FDA Ghana, SAHPRA, EFDA, TMDA, NDA and EDA in parallel. Module 3 is written once per molecule; Module 1 country adaptations, CPPs and legalisation chains are handled in-country through our regulatory correspondents. WHO-PQ and EAC joint-assessment routes are invoked where the product qualifies.
Prequalified programme lines
ARVs (TLD, TLE, raltegravir, zidovudine-lamivudine, lopinavir-ritonavir, paediatric dispersibles), ACTs (artemether-lumefantrine, artesunate-amodiaquine, artesunate injection), TB FDCs and reproductive-health lines including misoprostol, oxytocin and magnesium sulfate, sourced from manufacturers that hold WHO prequalification for the product. Donor-funded programme buyers usually require that status.
Central medical stores tender response
Full technical and commercial pack for KEMSA, NMS Uganda, JMS, MSD Tanzania, CMS Ghana and EPSS Ethiopia. Framework tenders run two to three years with annual refreshes; we track award calendars, pre-position stability and GMP artefacts, and coordinate local-agent filings. Award-to-first-shipment is typically six to ten weeks.
Cold-chain to Lagos, Mombasa, Durban, Addis, Accra
Envirotainer RAP e2 and RKN e1 active containers for 2-8°C biologicals, va-Q-tec passive shippers for 15-25°C ambient, real-time loggers on every pallet. Tarmac dwell at Lagos, Nairobi, Addis and Accra routinely hits 35-45°C; we route through cool-dolly hubs and destination warehousing is generator-backed.
NGO and programme procurement
Supply to NGO and donor-funded programme buyers, with products from manufacturers that hold the WHO prequalification those programmes ask for. Donor-specific serialisation, track-and-trace and visibility reporting are built into the dispatch pack as standard.
AMA, EAC, WAHO harmonisation-ready filings
Single dossier base re-used across EAC joint assessment, ECOWAS WAHO ARV and ACT fast-tracks, and future AMA continental assessment. Module 3 stays stable, country Module 1 adapts, artwork is versioned per market. A multi-country filing costs roughly the same as two single-country filings done blind.
Mumbai to Lagos, Mombasa and Durban.
Air is the fast lane. BOM-LOS, BOM-NBO, BOM-JNB, BOM-ADD and BOM-ACC run on an eight-to-sixteen-hour block depending on hub transit. Ethiopian Airlines is the workhorse into Addis and onward across East Africa. Kenya Airways connects Mombasa and Nairobi. Emirates SkyCargo and Qatar Airways run twice-daily widebody capacity via DXB and DOH into Lagos, Johannesburg, Nairobi and Accra. Turkish Cargo adds a third corridor via IST; Saudia Cargo backs up JED routings. Door-to-door for ambient pharmaceutical cargo runs four to seven working days on the East African corridor and five to nine working days on the West African corridor.
Sea is the volume channel. JNPT/Nhava Sheva to Apapa and Tin Can Island runs 21 to 26 days, Mombasa 14 to 18 days, Dar es Salaam 16 to 20 days, Durban 18 to 22 days, Tema 25 to 30 days and Abidjan 28 to 32 days. Maersk, CMA CGM and MSC run the core rotations; less-than-container-load consolidation is available for orders under 12 CBM. Bonded-warehouse options sit behind Mombasa for onward Kampala and Kigali distribution, and behind Durban for the SADC overland route into Zambia, Zimbabwe and Mozambique.
Cold-chain to warm-climate destinations is where most Indian exporters fail. Envirotainer RAP e2 active containers handle the 2-8°C corridor on larger tranches; RKN e1 handles smaller pharma-only shipments; va-Q-tec passive units carry 15-25°C controlled ambient where active power is not practical. Real-time loggers (Berlinger Q-tag CLm doc and ELPRO LIBERO) run on every cold-chain pallet, with a Bluetooth near-field unit for destination handoff. Tarmac dwell at Lagos, Nairobi and Addis routinely reaches 35-45°C; our excursion protocol triggers inside a 30-minute breach of the validated corridor.
Payment and insurance are sized to the buyer. Sovereign and central-stores buyers typically settle on donor-milestone releases or LC at sight through a first-tier African trade bank, with Afreximbank and the African Trade Insurance Agency layering credit-insurance cover where workable. Private hospital groups use TT 30% advance against 70% scanned BL, migrating to open account at 30 to 90 days once the relationship proves out. Cargo runs on Institute Cargo Clauses A, door-to-door.
What we ship most into Africa.
HIV, TB, malaria and reproductive health dominate programmatic volume. Our largest African dispatches sit in first-line antiretrovirals (TLD, tenofovir-lamivudine-dolutegravir, dolutegravir 50 mg, tenofovir-lamivudine, paediatric dispersible formulations), artemisinin-based combination therapies (artemether-lumefantrine, artesunate-amodiaquine, injectable artesunate for severe malaria), and anti-TB fixed-dose combinations across Category I, II and III regimens. Reproductive-health essentials move in consistent tender quantities: misoprostol, oxytocin, magnesium sulfate and methyldopa for pre-eclampsia. Demand flows primarily through Global Fund PPM awards, PEPFAR country programmes, UNICEF Supply Division paediatric ARV consolidations and President's Malaria Initiative pipelines.
Anti-infectives and maternal-health lines cover the broader hospital formulary. Ceftriaxone injection, amoxicillin-clavulanate, doxycycline, metronidazole, azithromycin and meropenem move through central stores and private hospital chains in both tender and direct-order formats. Oncology supportive care and cytotoxics route through private-sector groups such as Aga Khan University Hospital, Nairobi Hospital, Netcare, Lifehealthcare, Reddington Hospital, Mediclinic Southern Africa and regional oncology centres. Paclitaxel, gemcitabine, imatinib, 5-FU and oxaliplatin are the recurring lines; public-sector oncology procurement remains patchy and we do not overstate that channel.
Cardiometabolic and NCD volumes are the fastest-growing slice of the formulary in African tertiary hospitals. Hypertension and type-2 diabetes prevalence is rising across Lagos, Nairobi, Accra, Johannesburg and Addis, and hospital formularies pull steady tender volumes on metformin, glimepiride, amlodipine, telmisartan, losartan, atorvastatin and rosuvastatin. SGLT2 inhibitors and newer ARBs are emerging as tender-eligible lines in South Africa and Egypt. CNS, ophthalmology and critical-care injectables complete the hospital spine. Every line ships with country-specific artwork, CoA per batch and a current GMP certificate.
A Global Fund-funded implementing partner operating across three East African countries consolidated first-line antiretroviral supply under M Care from mid-2024. The scope covered TLD for adult cohorts and paediatric ARV dispersibles against a rolling twelve-month forecast, routed through Mombasa sea freight for the ambient lines and BOM-NBO air for cold-chain biologicals. Across the first 18 months of the arrangement, the programme recorded zero stock-outs at the facility level, a cold-chain excursion rate under 0.5% across 63 consignments, and an average dispatch-to-destination-arrival window of nine days on the air corridor and 19 days on the sea corridor. Temperature loggers were pulled and archived against every consignment; deviation reports were filed inside 24 hours on the two minor excursions that occurred, neither of which breached the stability corridor. The partner has since extended the framework into a second three-year cycle covering two additional therapeutic areas.
Why Indian pharma, why M Care, and what you actually get.
India manufactures roughly 20% of the world's generic finished dosage forms by volume and is the single largest source of antiretrovirals into sub-Saharan Africa through Global Fund and PEPFAR pooled procurement. The structural reasons are clear: WHO-GMP capacity at scale across more than 80 M Care partner sites, a deep API base that keeps finished-product cost 30-50% below European comparators for off-patent molecules, ICH-aligned stability programmes running at Zone IVb (30°C/75%RH), the most demanding long-term condition WHO lists for African markets, and English-language documentation that slots into NAFDAC, PPB, FDA Ghana, SAHPRA and EFDA dossiers without translation friction. Arabic adaptations for EDA are handled in-house.
The harder question is which Indian supplier. The African market has seen its share of one-container importers who disappear after the first pharmacovigilance query, manufacturers that under-quote and then default on the LC, and consultants who file CPPs authenticated incorrectly and leave the importer with an 18-month stall. M Care sits on the other side of that line. Our Mumbai head office is the regulatory engine room: dossier authoring, CMC review, stability coordination, pharmacovigilance intake and QP release all happen there. Our London desk handles the European-origin audit trail for donor programmes wanting a UK-visibility layer.
Three specifics distinguish the working relationship. First, a single named account manager for your African portfolio, not a rotating pool, with one mobile number and one email from RFQ through re-order. Second, programme lines sourced from manufacturers that hold WHO prequalification for the product, with the listing shown in the tender pack. Third, multi-country dossier re-use: the same Module 3 anchors NAFDAC, PPB, FDA Ghana, SAHPRA, EFDA, TMDA, NDA and EDA filings, so a four-country footprint costs meaningfully less than four blind single-country filings.
What you will not get: padded lead times, price ratchets on repeat orders, or the documentation gaps that show up three weeks before a KEMSA or NMS tender submission deadline. What you will get: WHO-GMP-sourced product with audit-ready paperwork, a Mumbai engine room that treats a Kampala hospital purchase order with the same seriousness as a London teaching-hospital contract, and honest visibility on what the dossier, the lane and the logger tell you at every step.
Africa pharmaceutical import: common questions.
Which African regulators does M Care routinely file with?
Eight: NAFDAC in Nigeria, PPB in Kenya, FDA Ghana, SAHPRA in South Africa, EFDA in Ethiopia, TMDA in Tanzania, NDA in Uganda and EDA in Egypt. Every dossier is built in ICH CTD or eCTD format with country-specific Module 1 adaptations. Where a molecule qualifies, the same dossier can support the manufacturer's applications on the WHO prequalification and EAC joint-assessment routes. CPPs and legalisation chains are managed centrally by the Mumbai team.
Is WHO prequalification required for African tender supply?
For programmatic buys on antiretrovirals, ACTs, anti-TB fixed-dose combinations and reproductive-health commodities, WHO-PQ status is usually either a precondition or a material scoring advantage. Global Fund PPM buys and UNICEF Supply Division paediatric ARV consolidations are WHO-PQ-gated by policy. For non-programmatic hospital formulary lines, country national registration is sufficient. For those lines, M Care sources from manufacturers that hold WHO prequalification for the product.
Does M Care supply donor-funded programmes such as the Global Fund, PEPFAR and UNICEF?
We supply the NGOs, implementing partners and humanitarian buyers that deliver donor-funded programmes, with products from manufacturers that hold the WHO prequalification or stringent-authority approval the programme asks for. Tell us the programme and its quality-assurance policy, and we confirm the source before quoting. Donor-specific serialisation and visibility reporting are standard on the dispatch pack.
What is the AMA and how does it affect multi-country registration?
AMA is the African Medicines Agency, the continental regulator envisaged under the African Union treaty that entered into force on 5 November 2019. The secretariat is being stood up in Kigali and operational rollout is phased through the late 2020s. AMA does not yet replace national registration with NAFDAC, PPB, SAHPRA or EDA. It will progressively provide a continental pathway for priority medicines. We author dossiers today in a structure that will re-use into AMA assessment.
How does cold-chain work to warm-climate destinations?
Validated active containers on the 2-8°C corridor (Envirotainer RAP e2 or RKN e1), va-Q-tec passive units on the 15-25°C corridor, continuous temperature logging through Berlinger Q-tag and ELPRO LIBERO loggers, cool-dolly handover at transit and destination, and a generator-backed warehouse with 72-hour autonomy. Tarmac dwell at Lagos, Nairobi, Addis and Accra runs 35-45°C in peak season. Excursion protocol triggers at a 30-minute breach.
Can M Care bid on central-medical-stores tenders?
Yes. We file into KEMSA, NMS Uganda, JMS Uganda, MSD Tanzania, CMS Ghana, EPSS Ethiopia and the relevant Francophone regional stores. Tender cycles run two to three years with annual refreshes. We pre-position the technical pack (CTD extract, stability under Zone IVb, GMP certificate, CPP, WHO-PQ status where applicable, artwork and pro-forma) and coordinate the local-agent filings each store requires.
How long does NAFDAC product registration take?
NAFDAC's registration guideline sets 240 working days from acceptance of the submission to the registration number, with the clock stopped while the applicant answers queries; an application whose queries go unanswered for 90 working days is closed. A complete dossier with a valid WHO-GMP certificate, CoPP, Zone IVb stability data and bioequivalence documentation keeps those stops few, and we answer queries inside two weeks.
Do you supply Francophone and Anglophone African markets?
Yes. Anglophone West Africa runs through NAFDAC and FDA Ghana under ECOWAS WAHO harmonisation. Anglophone East Africa runs through PPB, NDA, TMDA and the EAC joint-assessment programme. Southern Africa runs through SAHPRA. In francophone West Africa, the UEMOA rules require Module 1 of the CTD in each country's official language, French, and set no language for the other modules; Cameroon accepts dossiers in French or English. North Africa has a separate regulator in each country, such as EDA in Egypt and ANPP in Algeria; Egypt requires an Arabic patient leaflet for most products and Algeria requires product texts legible in Arabic.
Why buyers choose M Care for the India → Africa corridor.
Multi-regulator fluency
Dossiers built to the exact format NAFDAC, PPB, FDA Ghana, SAHPRA, EFDA, TMDA, NDA and EDA reviewers read, not a generic CTD dump. We know which modules each authority scrutinises first, which stability windows trigger queries, and which legalisation and apostille chain each submission needs to clear on the first pass. WHO-PQ and EAC joint-assessment pathways are invoked where the molecule qualifies.
Logistics for warm-climate freight
Validated Envirotainer and va-Q-tec cold-chain kit across BOM-LOS, BOM-NBO, BOM-JNB, BOM-ADD and BOM-ACC, continuous temperature logging, cool-dolly handover at transit hubs, and generator-backed destination warehousing with 72-hour autonomy. Tarmac dwell at 35-45°C is a design constraint, not a surprise. Excursion protocol triggers inside 30 minutes.
Commercial discipline, one point of contact
USD, EUR or GBP invoicing with clear FX-clause language, LC at sight and donor-milestone settlement options for sovereign and NGO buyers, open-account progression as the relationship proves out, 18 therapeutic areas on one purchase order, and one named account manager from enquiry through clearance at destination. No rotating pool.
Top categories we ship to Africa
Anti-infectives
ARVs, ACTs, anti-TB FDCs, cephalosporins, carbapenems, antifungals, antivirals. Lines from WHO-prequalified manufacturers serve donor-funded programmes; the broader hospital formulary covers ceftriaxone, meropenem and azithromycin.
Oncology
Cytotoxics and supportive care for private-sector hospital chains: paclitaxel, gemcitabine, imatinib, 5-FU, oxaliplatin. Aga Khan, Nairobi Hospital, Netcare, Lifehealthcare and Reddington are representative buyers.
Cardiovascular
Antihypertensives, statins, antiarrhythmics and heart-failure lines: amlodipine, telmisartan, losartan, atorvastatin, rosuvastatin. Rising tender volumes across South Africa, Kenya, Nigeria and Egypt.
Diabetes & endocrine
Metformin, glimepiride, newer SGLT2 inhibitors in South Africa and Egypt, thyroid and hormonal therapy, human and analogue insulins in validated cold-chain across 470+ lines.
CNS & neurology
Antiepileptics, antipsychotics, antidepressants, anxiolytics and neuroprotective lines supporting teaching hospitals and psychiatric services across the continent.
General & OTC
Analgesics, vitamins, wound-care, nutritionals and maternal-health commodities, 1,283 SKUs, the broadest slice of the catalogue, with both tender and private-retail channels served.
Country-level pages.
Routes that sit behind this region.
NGO pharmaceutical procurement
Supply to NGO and donor-funded programme buyers from manufacturers that hold the quality approvals those programmes require. Donor-specific serialisation, visibility reporting and milestone-release settlement built in as standard.
WHO-GMP compliance
WHO-GMP-sourced finished dosage forms across 80+ partner sites, with CDSCO export licensure, CPPs, apostille and legalisation handled centrally. WHO TRS 986 Annex 2 and WHO-PQ inspection-ready documentation, audit trail-complete on every dispatch.
Cold-chain validation
Envirotainer RAP e2, RKN e1 and va-Q-tec passive systems qualified for 2-8°C and 15-25°C corridors. Real-time Berlinger and ELPRO logging, excursion protocol at 30-minute breach, generator-backed destination warehousing with 72-hour autonomy.
One desk behind the continent's tender, donor and hospital channels.
Government supply services
Technical-pack pre-positioning and tender response for KEMSA, NMS Uganda, JMS, MSD Tanzania, CMS Ghana and EPSS Ethiopia framework cycles, local-agent filings coordinated alongside each store's own submission calendar.
NGO and donor-programme procurement
NGO, implementing-partner and humanitarian buyers on donor-funded programmes, with sources that meet each programme's quality-assurance policy, one desk.
WHO-GMP compliance
Manufacturers' WHO-GMP certificates, and WHO prequalification where the product needs it, with CPP and legalisation chains built to what NAFDAC, PPB and SAHPRA each expect.
Dossier preparation, CTD and eCTD
A single Module 3 substrate carries into NAFDAC, PPB, FDA Ghana, SAHPRA, EFDA, TMDA, NDA and EDA filings, with EAC joint assessment and ECOWAS WAHO fast-tracks invoked wherever the molecule qualifies for them.
Cold-chain validation
Envirotainer RAP e2 and va-Q-tec kit qualified against the Lagos, Nairobi, Addis and Accra tarmac dwell, Berlinger Q-tag and ELPRO LIBERO logging on every pallet, excursion protocol triggered inside a 30-minute breach.
Country guides for buyers sourcing into Africa.
Nigeria: NAFDAC registration
The dossier, GMP inspection and realistic timelines for registering and importing medicines into Nigeria.
Ghana: FDA registration and the local agent
How Ghana's FDA registers medicines under Act 851, and why the mandatory local agent is the gate everything else waits behind.
Kenya: KEMSA, MEDS and the PPB
Two public medicine buyers and three separate Pharmacy and Poisons Board gates, and what exporters and importers each need to clear.
Uganda: NDA registration and import permits
How the National Drug Authority registers medicines, licenses importers and clears consignments, plus the NMS and JMS procurement routes.
Tanzania: the TMDA accelerated pathway
How WHO-prequalified generics move through TMDA's accelerated route, and where the delays tend to happen.
Ethiopia: EFDA registration and import permits
Product registration, the Certificate of Competence, pre-import permits and EPSS tenders for medicines sourced from India.
Zambia: ZAMRA registration and import permits
Marketing Authorisation, the licensed Zambian wholesaler, per-shipment import permits and ZAMMSA public procurement.
Zimbabwe: MCAZ registration and imports
Who may import into Zimbabwe, per-consignment permits, NatPharm's role and the document pack Indian suppliers provide.
Senegal: ARP registration and import from India
How medicine registration and import work in Senegal: the ARP regulator, pharmacist-led importers, SEN-PNA tenders and the Indian document pack.
South Africa: SAHPRA registration and imports from India
How SAHPRA registration, Section 21 access, importer licensing and NDoH tenders work for Indian medicines, and the document pack a South African importer needs.
Molecule, volume, target market. One working day to a quote.
Your enquiry lands with the named account manager for the African corridor. Regulatory, logistics and commercial answers in the turnaround your tender file needs.
Start an Africa enquiry → Back to all marketsBuying for repeat supply? Open a trade account for a named account manager and priced quotes.